Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPULSE: Empagliflozin in Acute Heart Failure
NCT04157751Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of empagliflozin in Acute Heart Failure (AHF), sponsored by Boehringer Ingelheim. Started May 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT04157751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157751.